Adoptive cell transfer therapy for hepatocellular carcinoma.
10.1007/s11684-019-0684-x
- Author:
Renyu ZHANG
1
;
Zhao ZHANG
1
;
Zekun LIU
1
;
Ding WEI
1
;
Xiaodong WU
1
;
Huijie BIAN
2
;
Zhinan CHEN
3
Author Information
1. Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, 710032, China.
2. Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, 710032, China. hjbian@fmmu.edu.cn.
3. Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, 710032, China. znchen@fmmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
T cell;
adoptive cell transfer therapy;
chimeric antigen receptor;
hepatocellular carcinoma;
immunotherapy
- MeSH:
Adoptive Transfer;
methods;
Carcinoma, Hepatocellular;
immunology;
therapy;
Humans;
Immunotherapy, Adoptive;
methods;
Liver Neoplasms;
immunology;
therapy;
Lymphocytes, Tumor-Infiltrating;
cytology;
Randomized Controlled Trials as Topic;
Receptors, Chimeric Antigen;
T-Lymphocytes;
cytology
- From:
Frontiers of Medicine
2019;13(1):3-11
- CountryChina
- Language:English
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This malignancy is associated with poor prognosis and high mortality. Novel approaches for prolonging the overall survival of patients with advanced HCC are urgently needed. The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltrating lymphocytes and cytokine-induced killer cells, are more effective than those of traditional strategies. Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma. Nevertheless, this approach only provides a modest benefit in the treatment of solid tumors. The clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited. Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side effects. In this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology in HCC treatment, and some possible strategies for the future direction of immunotherapeutic research.
